IMG-004 is under clinical development by Inmagene Biopharmaceuticals and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase I drugs for Multiple Sclerosis have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMG-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMG-004 overview

IMG-004 is under development for the treatment of multiple sclerosis. It acts by targeting Bruton's tyrosine kinase (BTK). It is administered through oral route as capsule formulation.

It was under development for the treatment of chronic spontaneous urticaria (CSU).

Inmagene Biopharmaceuticals overview

Inmagene Biopharmaceuticals (Inmagene) is a biotechnology company that discovers and develops drugs for immunology-related diseases. The company’s product pipeline comprises IMG-016 for immune thrombocytopenia, IMG-020 for psoriasis, IMG-004 for multiple sclerosis, IMG-007 for atopic dermatitis, IMG- 008 for generalized pustular psoriasis, and IMG-036 for asthma. It has a presence in Shanghai, San Diego, Hangzhou, Sydney, and Wuhan. Inmagene is headquartered in Shanghai, China.

For a complete picture of IMG-004’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.